| pubmed-article:21791652 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21791652 | lifeskim:mentions | umls-concept:C0042749 | lld:lifeskim |
| pubmed-article:21791652 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21791652 | lifeskim:mentions | umls-concept:C0013203 | lld:lifeskim |
| pubmed-article:21791652 | lifeskim:mentions | umls-concept:C0205322 | lld:lifeskim |
| pubmed-article:21791652 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:21791652 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21791652 | pubmed:dateCreated | 2011-7-27 | lld:pubmed |
| pubmed-article:21791652 | pubmed:abstractText | Population sequencing was performed for persons identified with persistent low-level viremia in 2 clinical trials. Persistent low-level viremia (defined as plasma HIV-1 RNA level >50 and <1000 copies/mL in at least 2 determinations over a 24-week period, after at least 24 weeks of antiretroviral therapy) was observed in 65 (5.6%) of 1158 patients at risk. New resistance mutations were detected during persistent low-level viremia in 37% of the 54 evaluable cases. The most common mutations were M184I/V (14 cases), K103N (9), and M230L (3). Detection of new mutations was associated with higher HIV-1 RNA levels during persistent low-level viremia. | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21791652 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21791652 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21791652 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21791652 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21791652 | pubmed:issn | 1537-6613 | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:EronJoseph... | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:HaubrichRicha... | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:KuritzkesDani... | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:TaiwoBabafemi... | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:AgaEvgeniaE | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:RibaudoHeathe... | lld:pubmed |
| pubmed-article:21791652 | pubmed:author | pubmed-author:GallienSebast... | lld:pubmed |
| pubmed-article:21791652 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21791652 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21791652 | pubmed:volume | 204 | lld:pubmed |
| pubmed-article:21791652 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21791652 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21791652 | pubmed:pagination | 515-20 | lld:pubmed |
| pubmed-article:21791652 | pubmed:dateRevised | 2011-10-28 | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:meshHeading | pubmed-meshheading:21791652... | lld:pubmed |
| pubmed-article:21791652 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21791652 | pubmed:articleTitle | Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. | lld:pubmed |
| pubmed-article:21791652 | pubmed:affiliation | Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA. b-taiwo@northwestern.edu | lld:pubmed |
| pubmed-article:21791652 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21791652 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21791652 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
